Bone Health

Hematology

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Compendia

Respiratory

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

E-News

Print Subscription

BIOSIMILAR APPROVALS

Videos

Here are the top 5 biosimilar articles for the week of March 27, 2023.

The Top 5 Biosimilar Articles for the Week of March 27

Articles

Yukon, 1 of 3 Canadian territories, announced that it will implement a biosimilars switching policy, following Newfoundland and Labrador’s announcement to move forward with a similar policy earlier this week.

Yukon Becomes Tenth Canadian Jurisdiction to Add Biosimilars Switching Policy

The Increasing Access to Biosimilars Act of 2023 (HR 1352), a bill that would direct HHS to establish a demonstration project within Medicare that would establish a shared savings model for biosimilars, was introduced to the House of Representatives.

The Increasing Access to Biosimilars Act of 2023 Introduced to Congress

Newfoundland and Labrador is the latest Canadian province to implement a biosimilar switching policy, following in the footsteps of Ontario and 7 other jurisdictions.

Canadian Province Newfoundland and Labrador Adds Biosimilar Switching Policy

About

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

Global Perspective on the Effect of Biosimilars

Comparison of Biologics to Biosimilars Versus Generics

The BPCIA and the Naming of Biosimilars

The Approval Process for Biosimilars

Considerations for Approving Generics Versus Biosimilars 

Interchangeability and Postmarketing Pharmacovigilance of Biosimilars

Experience Prescribing Biosimilars Versus Biologics

The Impact of Access to Biosimilars

US and EU Biosimilar Pricing and Stakeholder Education

Formulary Approval and Challenges for Payers

Prescribing Biosimilars and Educating Patients and Physicians 

The Influence of Biosimilars in Cancer Care

Biosimilars in the Pipeline and Disease Management

Outlook on the Future of Biosimilars 